SCHEMBL12780949

SCHEMBL12780949

Nc1nc(NCc2ccccc2)nn1-c1nc2ccccc2s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.51
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
MAPK1 P28482 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
APP P05067 2/20 0.44
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
AXL P30530 1/20 0.42
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12780913 0.89 NPC1 (0.54) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL12779030 0.86 BACE1 (0.52) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL14369943 0.85 APP (0.49) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL14369944 0.83 NPC1 (0.62) BACE1NPC1RAB9ASMN1; SMN2APP
SCHEMBL14369945 0.83 KMT2A (0.56) BACE1NPC1RAB9AALDH1A1MAPT
SCHEMBL12779066 0.82 BACE1 (0.63) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL12780915 0.81 ILK (0.51) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL12780970 0.80 BACE1 (0.49) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL12780873 0.78 BACE1 (0.61) BACE1NPC1RAB9AMAPK1ALDH1A1
SCHEMBL12780879 0.78 BACE1 (0.54) BACE1NPC1RAB9AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885NPC1 2770/4885RAB9A 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.